BioSpace News Archive

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 600,000 additional shares.

CytomX Therapeutics, Inc. announced that on November 15, 2019, the Company granted six new employees options to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share equal to $5.36, which was the closing trading price on November 15, 2019, the date of the grant.

Bristol-Myers Squibb Company (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced positive top-line results from KarMMa, a pivotal, open-label, single arm, multicenter, Phase 2 study of idecabtagene vicleucel (ide-cel; bb2121).

Dr. Reddy’s Laboratories Ltd. announced the launch of Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of Jadenu® Film-Coated Tablets, 90 mg, 180 mg, and 360 mg, approved by the U.S. Food and Drug Administration.

HEXO Corp. (“HEXO” or the “Company”) (TSX:HEXO; NYSE:HEXO) is pleased to announce the closing of its previously announced private placement of unsecured convertible debentures for aggregate gross proceeds of $70 million (the “Offering”).

Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that preliminary safety and efficacy data from an investigator-sponsored trial evaluating telaglenastat (CB-839) in combination with azacitidine will be presented in an oral session at the American Society of Hematology (ASH) Annual Meeting 2019 taking place December 7-10, in Orlando, Florida.

Global Cord Blood Corporation, China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, reported that China’s National Health Commission recently issued a new policy allowing the relevant Provincial Health Commissions to approve cord blood bank licenses in 18 pilot Free Trade Zones in China.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced preliminary tolerability and PK data from its ongoing Phase 1 dose-finding study of fimepinostat, a small molecule dual inhibitor of PI3K/HDAC and suppressor of MYC, in combination with venetoclax,

The board of directors of Medtronic plc (NYSE:MDT) today approved the fiscal year 2020 third quarter cash dividend of $0.54 per ordinary share, representing an 8 percent increase over the prior year.

Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored with a 2019 MarCom Platinum Award.